

Supplementary material: New Pyrroline Isolated from Antarctic Krill-Derived Actinomycetes *Nocardiopsis* LX-1 Combining with Molecular Networking

Ting Shi, Yan-Jing Li, Ze-Min Wang, Yi-Fei Wang, Bo Wang and Da-Yong Shi

Figure S1. ^1H NMR spectrum of compound **1** (CD_3OD).

Figure S2. ^{13}C NMR spectrum of compound **1** (CD_3OD).

Figure S3. HSQC spectrum of compound **1** (CD_3OD).

Figure S4. COSY spectrum of compound **1** (CD_3OD).

Figure S5. HMBC spectrum of compound **1** (CD_3OD).

Figure S6. NOESY spectrum of compound **1** (CD_3OD).

Figure S7. HR-ESI $^-$ -MS spectrum of compound **1**.

Figure S8. HR-ESI $^+$ -MS spectrum of compound **1**.

Figure S9. IR spectrum of compound **1**.

Figure S10. ^1H NMR spectrum of compound **2** ($\text{DMSO}-d_6$).

Figure S11. ^{13}C NMR spectrum of compound **2** ($\text{DMSO}-d_6$).

Figure S12. HR-ESI $^-$ -MS spectrum of compound **2**.

Figure S13. HR-ESI $^+$ -MS spectrum of compound **2**.

Figure S14. ^1H NMR spectrum of compound **3** (CDCl_3).

Figure S15. ^{13}C NMR spectrum of compound **3** (CDCl_3).

Figure S16. HR-ESI $^-$ -MS spectrum of compound **3**.

Figure S17. HR-ESI $^+$ -MS spectrum of compound **3**.

Figure S18. ^1H NMR spectrum of compound **4** (CDCl_3).

Figure S19. ^{13}C NMR spectrum of compound **4** (CDCl_3).

Figure S20. HR-ESI $^-$ -MS spectrum of compound **4**.

Figure S21. HR-ESI $^+$ -MS spectrum of compound **4**.

Figure S22. ^1H NMR spectrum of compound **5** (CD_3OD).

Figure S23. ^{13}C NMR spectrum of compound **5** (CD_3OD).

Figure S24. HR-ESI $^-$ -MS spectrum of compound **5**.

Figure S25. HR-ESI $^+$ -MS spectrum of compound **5**.

Figure S26. ^1H NMR spectrum of compound **6** (CDCl_3).

Figure S27. ^{13}C NMR spectrum of compound **6** (CDCl_3).

Figure S28. HR-ESI $^-$ -MS spectrum of compound **6**.

Figure S29. HR-ESI $^+$ -MS spectrum of compound **6**.

Figure S30. ^1H NMR spectrum of compound **7** (CDCl_3).

Figure S31. ^{13}C NMR spectrum of compound **7** (CDCl_3).

Figure S32. HR-ESI $^-$ -MS spectrum of compound **7**.

Figure S33. HR-ESI $^+$ -MS spectrum of compound **7**.

Figure S34. ^1H NMR spectrum of compound **8** (CD_3OD).

Figure S35. ^{13}C NMR spectrum of compound **8** (CD_3OD).

Figure S36. HR-ESI $^-$ -MS spectrum of compound **8**.

Figure S37. HR-ESI $^+$ -MS spectrum of compound **8**.

Figure S38. ^1H NMR spectrum of compound **9** (DMSO- d_6).

Figure S39. ^{13}C NMR spectrum of compound **9** (DMSO- d_6).

Figure S40. HR-ESI $^-$ -MS spectrum of compound **9**.

Figure S41. ^1H NMR spectrum of compound **10** (DMSO- d_6).

Figure S42. ^{13}C NMR spectrum of compound **10** (DMSO- d_6).

Figure S43. HR-ESI $^-$ -MS spectrum of compound **10**.

Figure S44. HR-ESI $^+$ -MS spectrum of compound **10**.

Figure S45. ^1H NMR spectrum of compound **11** (CD₃OD).

Figure S46. ^{13}C NMR spectrum of compound **11** (CD₃OD).

Figure S47. HR-APCI-MS spectrum of compound **11**.

Figure S48. ^1H NMR spectrum of compound **12** (CDCl₃).

Figure S49. ^{13}C NMR spectrum of compound **12** (CDCl₃).

Figure S50. HR-ESI $^-$ -MS spectrum of compound **12**.

Figure S51. HR-ESI $^+$ -MS spectrum of compound **12**.

Figure S52. MS/MS spectrum of compound **a** (black) compared with GNPS library spectrum (green).

Figure S53. MS/MS spectrum of compound **b** (black) compared with GNPS library spectrum (green).

Figure S54. MS/MS spectrum of compound **c** (black) compared with GNPS library spectrum (green).

Figure S55. MS/MS spectrum of compound **d** (black) compared with GNPS library spectrum (green).

Figure S56. MS/MS spectrum of compound **e** (black) compared with GNPS library spectrum (green).

Figure S57. MS/MS spectrum of compound **f** (black) compared with GNPS library spectrum (green).

Figure S58. MS/MS spectrum of compound **g** (black) compared with GNPS library spectrum (green).

Figure S59. MS/MS spectrum of compound **h** (black) compared with GNPS library spectrum (green).

Figure S60. MS/MS spectrum of compound **i** (black) compared with GNPS library spectrum (green).

Figure S61. MS/MS spectrum of compound **j** (black) compared with GNPS library spectrum (green).

Figure S62. MS/MS spectrum of compound **k** (black) compared with GNPS library spectrum (green).

Figure S63. MS/MS spectrum of compound **l** (black) compared with GNPS library spectrum (green).

Figure S64. MS/MS spectrum of compound **m** (black) compared with GNPS library spectrum (green).

Figure S65. MS/MS spectrum of compound **n** (black) compared with GNPS library spectrum (green).

Figure S66. MS/MS spectrum of compound **o** (black) compared with GNPS library spectrum (green).

Figure S67. MS/MS spectrum of compound **p** (black, [M+H] $^+$) compared with GNPS library spectrum (green).

Figure S68. MS/MS spectrum of compound **p** (black, [M+Na] $^+$) compared with GNPS library spectrum (green).

Table S1. NMR spectroscopic data (400/100 MHz) of daidzein (**2**) in DMSO- d_6 .

Table S2. ^1H NMR spectroscopic data (400 MHz) of compounds **3–8** in CDCl₃.

Table S3. ^{13}C NMR spectroscopic data (100 MHz) of compounds **3–8** in CDCl₃.

Table S4. Specific OR of cyclic dipeptides **3–8** in MeOH.

Table S5. NMR spectroscopic data (400/100 MHz) of compounds **9–12**.




Figure S1. ^1H NMR spectrum of compound **1** (CD_3OD).




Figure S2. ^{13}C NMR spectrum of compound **1** (CD_3OD).




Figure S3. HSQC spectrum of compound **1** (CD_3OD).




Figure S4. COSY spectrum of compound **1** (CD_3OD).




Figure S5. HMBC spectrum of compound **1** (CD_3OD).








Figure S6. NOESY spectrum of compound **1** (CD_3OD).

**Figure S7.** HR-ESI⁻-MS spectrum of compound **1**.**Figure S8.** HR-ESI⁺-MS spectrum of compound **1**.

**Figure S9.** IR spectrum of compound 1.**Figure S10.** ¹H NMR spectrum of compound 2 (DMSO-*d*₆).




Figure S11. ^{13}C NMR spectrum of compound 2 (DMSO- d_6).

L-322 #10 RT: 0.16 AV: 1 SB: 35 0.01-0.07 , 0.52-1.03 NL: 7.99E4
T: FTMS {1,2} - p ESI Full ms [50.00-750.00]




Figure S12. HR-ESI-MS spectrum of compound 2.

L-322 #13 RT: 0.21 AV: 1 NL: 2.03E4
 T: FTMS (1,1) + p ESI Full ms [50.00-750.00]




Figure S13. HR-ESI⁺-MS spectrum of compound **2**.




Figure S14. ¹H NMR spectrum of compound **3** (CDCl_3).




Figure S15. ^{13}C NMR spectrum of compound **3** (CDCl_3).




Figure S16. HR-ESI⁻-MS spectrum of compound **3**.

L-422 #11 RT: 0.18 AV: 1 NL: 5.03E4
T: FTMS {1,1} + p ESI Full ms [50.00-750.00]




Figure S17. HR-ESI⁺-MS spectrum of compound 3.




Figure S18. ¹H NMR spectrum of compound 4 (CDCl₃).




Figure S19. ^{13}C NMR spectrum of compound 4 (CDCl_3).




Figure S20. HR-ESI⁻-MS spectrum of compound 4.

L-423 #11 RT: 0.17 AV: 1 NL: 1.13E5
T: FTMS {1,1} + p ESI Full ms [50.00-750.00]




Figure S21. HR-ESI⁺-MS spectrum of compound 4.




Figure S22. ¹H NMR spectrum of compound 5 (CD₃OD).




Figure S23. ^{13}C NMR spectrum of compound 5 (CD_3OD).

L-4331 #16 RT: 0.26 AV: 1 SB: 35 0.01-0.07 , 0.52-1.03 NL: 2.93E5
T: FTMS {1,2} - p ESI Full ms [50.00-750.00]






Figure S24. HR-ESI⁻-MS spectrum of compound 5.

**Figure S25.** HR-ESI⁺-MS spectrum of compound 5.**Figure S26.** ¹H NMR spectrum of compound 6 (CDCl₃).




Figure S27. ^{13}C NMR spectrum of compound **6** (CDCl_3).

L-424 #16 RT: 0.26 AV: 1 SB: 35 0.01-0.07 , 0.52-1.02 NL: 2.12E5
T: FTMS {1,2} - p ESI Full ms [50.00-750.00]




Figure S28. HR-ESI⁻-MS spectrum of compound **6**.

L-424 #11 RT: 0.18 AV: 1 NL: 7.90E4
T: FTMS {1,1} + p ESI Full ms [50.00-750.00]




Figure S29. HR-ESI⁺-MS spectrum of compound 6.




Figure S30. ¹H NMR spectrum of compound 7 ($CDCl_3$).




Figure S31. ^{13}C NMR spectrum of compound 7 (CDCl_3).




Figure S32. HR-ESI⁻-MS spectrum of compound 7.

L-434 #13 RT: 0.21 AV: 1 NL: 1.39E5
T: FTMS {1,1} + p ESI Full ms [50.00-750.00]





Figure S33. HR-ESI⁺-MS spectrum of compound 7.






Figure S35. ^{13}C NMR spectrum of compound 8 (CD_3OD).




Figure S36. HR-ESI-MS spectrum of compound 8.




Figure S37. HR-ESI⁺-MS spectrum of compound **8**.






Figure S38. ^1H NMR spectrum of compound **9** ($\text{DMSO}-d_6$).

**Figure S39.** ^{13}C NMR spectrum of compound **9** (DMSO- d_6).**Figure S40.** HR-ESI $^-$ -MS spectrum of compound **9**.




Figure S41. ^1H NMR spectrum of compound **10** ($\text{DMSO}-d_6$).




Figure S42. ^{13}C NMR spectrum of compound **10** ($\text{DMSO}-d_6$).

L-421 #10 RT: 0.16 AV: 1 SB: 35 0.01-0.07 , 0.52-1.02 NL: 1.53E5
T: FTMS {1,2} - p ESI Full ms [50.00-750.00]




Figure S43. HR-ESI⁻-MS spectrum of compound **10**.

L-421 #11 RT: 0.18 AV: 1 NL: 5.82E3
T: FTMS {1,1} +p ESI Full ms [50.00-750.00]






Figure S44. HR-ESI⁺-MS spectrum of compound **10**.

**Figure S45.** ^1H NMR spectrum of compound **11** (CD_3OD).**Figure S46.** ^{13}C NMR spectrum of compound **11** (CD_3OD).

L-331_230109152052 #5 RT: 0.06 AV: 1 NL: 6.93E6
 T: FTMS {1,1} + p APCI corona Full ms [50.00-500.00]




Figure S47. HR-APCI-MS spectrum of compound **11**.




Figure S48. ^1H NMR spectrum of compound **12** (CDCl_3).




Figure S49. ^{13}C NMR spectrum of compound **12** (CDCl_3).

L-2 #26 RT: 0.43 AV: 1 SB: 35 0.01-0.07 , 0.52-1.02 NL: 3.27E4
T: FTMS {1,2} - p ESI Full ms [50.00-750.00]




Figure S50. HR-ESI-MS spectrum of compound **12**.

L-2 #11 RT: 0.18 AV: 1 NL: 1.32E4
T: FTMS (1,1) + p ESI Full ms [50.00-750.00]




Figure S51. HR-ESI⁺-MS spectrum of compound 12.




Figure S52. MS/MS spectrum of compound a (black) compared with GNPS library spectrum (green).




Figure S53. MS/MS spectrum of compound **b** (black) compared with GNPS library spectrum (green).




Figure S54. MS/MS spectrum of compound **c** (black) compared with GNPS library spectrum (green).




Figure S55. MS/MS spectrum of compound **d** (black) compared with GNPS library spectrum (green).




Figure S56. MS/MS spectrum of compound **e** (black) compared with GNPS library spectrum (green).




Figure S57. MS/MS spectrum of compound **f** (black) compared with GNPS library spectrum (green).




Figure S58. MS/MS spectrum of compound **g** (black) compared with GNPS library spectrum (green).




Figure S59. MS/MS spectrum of compound **h** (black) compared with GNPS library spectrum (green).




Figure S60. MS/MS spectrum of compound **i** (black) compared with GNPS library spectrum (green).




Figure S61. MS/MS spectrum of compound **j** (black) compared with GNPS library spectrum (green).




Figure S62. MS/MS spectrum of compound **k** (black) compared with GNPS library spectrum (green).




Figure S63. MS/MS spectrum of compound **I** (black) compared with GNPS library spectrum (green).




Figure S64. MS/MS spectrum of compound **m** (black) compared with GNPS library spectrum (green).




Figure S65. MS/MS spectrum of compound **n** (black) compared with GNPS library spectrum (green).




Figure S66. MS/MS spectrum of compound **o** (black) compared with GNPS library spectrum (green).




Figure S67. MS/MS spectrum of compound **p** (black, $[M+H]^+$) compared with GNPS library spectrum (green).




Figure S68. MS/MS spectrum of compound **p** (black, $[M+Na]^+$) compared with GNPS library spectrum (green).

Table S1. NMR spectroscopic data (400/100 MHz) of daidzein (**2**) in DMSO-*d*₆.

Position	δ_{C}	δ_{H} (<i>J</i> in Hz)
2	152.4, CH	8.20, s
3	123.3, C	
4	174.6, C	
5	127.0, CH	7.87, d (8.8)
6	115.0, CH	6.82, dd (8.8, 2.2)
7	158.9, C	
8	102.0, CH	6.69, d (2.2)
9	158.0, C	
10	116.5, C	
1'	122.9, C	
2'	130.1, CH	7.36, d (8.6)
3'	115.0, CH	6.79, d (8.6)
4'	157.0, C	
5'	115.0, CH	6.79, d (8.6)
6'	130.1, CH	7.36, d (8.6)

Table S2. ¹H NMR spectroscopic data (400 MHz) of compounds **3–8** in CDCl₃.

No.	3	4	5 ^a	6	7	8 ^a
3	3.76–3.70, m; 3.55–3.46, m	3.67, dt (12.0, 4.1); 3.49, ddd (12.0, 8.7, 2.8)	3.67, dd (13.1, 5.1); 3.28–3.26, m	3.67–3.61, m; 3.61–3.42, m	3.56, dt (12.1, 8.4); 3.33, ddd (12.1, 9.1, 2.9)	3.63, dd (12.8, 4.3); 3.41, dd (12.8, 1.6)
4	2.10–1.97, m; 1.95–1.78, m	1.96–1.81, m	4.24, t (4.6)	2.05–1.95, m; 1.95–1.79, m	1.77–1.57, m	4.44, t (4.3)
5	2.46–2.33, m; 1.95–1.78, m	2.47–2.31, m; 1.96–1.81, m	2.03, ddd (13.0, 5.9, 1.3); 1.32, ddd (13.0, 11.8, 4.6)	2.29, td (6.4, 3.6); 1.95–1.79, m	2.19–2.04, m; 1.95–1.82, m	2.25, ddt (13.3, 6.5, 1.6); 2.06, ddd (13.3, 11.2, 4.3)
6	4.07, dd (10.1, 5.6)	4.07, dd (9.9, 6.4)	4.33, ddd (11.8, 5.9, 2.0)	4.05, ddd (8.7, 6.6, 1.7) 5.81, br s	2.73, dd (10.6, 6.4)	4.50, ddd (11.2, 6.5, 1.6)
8-NH						
9	3.70–3.62, m	3.77, dd (5.7, 3.9)	4.45, td (5.1, 1.8)	4.26, dd (10.7, 3.0)	4.24–4.20, m	4.15, ddd (6.6, 4.4, 1.8)
10	2.24–2.16, m	2.15–1.96, m	3.13, dd (5.1, 1.8)	2.78, dd (14.5, 10.7); 3.61–3.42, m	3.16, dd (13.6, 5.8); 3.02, dd (13.6, 4.3)	1.95–1.80, m; 1.56–1.42, m
11	1.03, dd (7.1, 4.0)	1.54, ddd (13.2, 7.4, 4.0); 1.31–1.12, m				1.95–1.80, m
12	0.97, dd (6.9, 4.2)	0.90, t (7.4)				0.94, d (2.4)
13						0.93, d (2.3)
4-Me		0.99, d (6.9)				
2'			7.27–7.18, m	7.36–7.18, m	7.28–7.15, m	
3'			7.27–7.18, m	7.36–7.18, m	7.28–7.15, m	
4'			7.27–7.18, m	7.36–7.18, m	7.28–7.15, m	

5'		7.27–7.18, m	7.36–7.18, m	7.28–7.15, m
6'		7.27–7.18, m	7.36–7.18, m	7.28–7.15, m

a: NMR spectrum measured in CD₃OD

Table S3. ¹³C NMR spectroscopic data (100 MHz) of compounds **3–8** in CDCl₃.

No.	3	4	5^a	6	7	8^a
1	169.9, C	169.8, C	166.9, C	169.6, C	165.0, CH	168.8, C
3	45.7, CH ₂	45.7, CH ₂	55.0, CH ₂	45.5, CH ₂	45.1, CH ₂	54.3, CH ₂
4	22.0, CH ₂	39.8, CH	68.3, CH	22.6, CH ₂	21.7, CH ₂	68.9, CH
5	29.5, CH ₂	29.5, CH ₂	37.8, CH ₂	28.4, CH ₂	29.0, CH ₂	37.9, CH ₂
6	58.4, CH	58.5, CH	58.1, CH	59.2, CH	57.8, CH	58.5, CH
7	165.5, C	165.5, C	171.0, C	165.2, C	169.8, C	172.9, C
9	63.5, CH	62.9, CH	57.4, CH	56.3, CH	58.9, CH	54.9, CH
10	33.3, CH	22.1, CH ₂	38.6, CH ₂	36.8, CH ₂	40.5, CH ₂	39.1, CH ₂
11	19.1, CH ₃	24.6, CH ₂				25.5, CH
12	17.7, CH ₃	11.4, CH ₃				22.0, CH ₃
13						23.1, CH ₃
4-Me		15.4, CH ₃				
1'			137.2, C	136.1, C	135.4, C	
2'			130.8, CH	129.33, CH	130.1, CH	
3'			129.3, CH	129.27, CH	128.7, CH	
4'			127.9, CH	127.62, CH	127.6, CH	
5'			129.3, CH	129.27, CH	128.7, CH	
6'			130.8, CH	129.33, CH	130.1, CH	

a: NMR spectrum measured in CD₃OD

Table S4. Specific OR of cyclic dipeptides **3–8** in MeOH.

Compounds	Natural $[\alpha]_D^{20}$ (0.033, MeOH)	Literature
3	+147.15°	$[\alpha]_D^{25} +193^\circ$ (0.3, MeOH) [30]
4	+141.14°	$[\alpha]_D^{20} +128^\circ$ (0.1, EtOH) [31]
5	-174.17°	$[\alpha]_D^{20} -48.1^\circ$ (0.1, MeOH) [32]
6	-168.17°	$[\alpha]_D^{25} -60.6^\circ$ (0.66, EtOH) [33]
7	+114.11°	$[\alpha]_D^{20} +67.0^\circ$ (MeOH) [34]
8	-282.28°	$[\alpha]_D -77.8^\circ$ (0.38, MeOH) [35]

Table S5. NMR spectroscopic data (400/100 MHz) of compounds **9–12**.

No.	9^a δ _C	9 δ _H	10^a δ _C	10 δ _H	11^b δ _C	11 δ _H	12^c δ _C	12 δ _H
1					194.7, C		109.7, C	
2	151.0, C		151.6, C		128.1, C		151.2, C	
3					132.7, CH	8.18, d (2.8)	116.6, CH	6.67, dd (7.1, 1.0)
4	163.5, C		164.4, C		131.2 C		135.2, CH	7.30, ddd (8.3, 7.1, 1.6)
5	127.5, CH	7.87, dd (8.3, 1.6)	100.3, CH	5.44, dd (7.4, 1.9)	121.3, CH	8.21, ddd (6.6, 2.8, 1.4)	116.9, CH	6.66, dd (8.3, 1.0)

6	122.7, CH	7.17–7.13, m	142.3, CH	7.39, dd (7.4, 5.6)	121.9, CH	7.24–7.18, m	132.3, CH	7.92, dd (8.3, 1.6)
7	135.4, CH	7.62, ddd (8.5, 7.3, 1.6)			123.0, CH	7.24–7.18, m	173.6, C	
8	116.0, CH	7.17–7.13, m			111.6, CH	7.44, dd (6.5, 2.3)		
9	141.8, C				113.5, C			
10	114.9, C				64.9, CH ₂	4.72, d (2.8)		
1-NH				10.83, br s				
3-NH		11.23, br s		11.03, br s				

a: NMR spectrum measured in DMSO-*d*₆; b: NMR spectrum measured in CD₃OD; c: NMR spectrum measured in CDCl₃